Bristol-Myers Squibb vs Samsung: Founders, CEOs and History
Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner. Samsung was founded in 1969 by Lee Byung-chul and is led by Jun Young-hyun and Roh Tae-moon.
Company facts
Bristol-Myers Squibb
- Founded
- 1887
- Headquarters
- Princeton, New Jersey
- Current CEO
- Christopher Boerner
- Employees
- 32,500
Samsung
- Founded
- 1969
- Headquarters
- Suwon, South Korea
- Current CEO
- Jun Young-hyun and Roh Tae-moon
- Employees
- 259,149
Founders
Bristol-Myers Squibb
Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.
Samsung
Lee Byung-chul
Lee Byung-chul founded Samsung Sanghoe in Daegu in 1938, trading dried fish, produce and noodles.
CEOs and their tenures
Bristol-Myers Squibb
- Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source - Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source - James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source - Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source - Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source - Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source
Samsung
- Jong-Hee Han2022–2025
Vice Chairman and CEO
A longtime TV business leader who helped keep Samsung the top global TV brand. He died suddenly in March 2025 while in office.
Source - Jay Y. Lee2022–present
Executive Chairman
Grandson of the founder and son of Lee Kun-hee. He was convicted in the 2017 bribery case and pardoned in 2022, and became Executive Chairman in October 2022. In 2025 the Supreme Court upheld his acquittal in the separate merger and accounting fraud case.
Source - Jun Young-hyun2024–present
Vice Chairman, Co-Chief Executive Officer, Head of Device Solutions
He implemented a complete overhaul of the semiconductor division's engineering processes, issuing a rare public apology in 2024 for the company's technological delays.
Source - Roh Tae-moon (TM Roh)2025–present
Co-Chief Executive Officer, Head of Device eXperience
As head of the MX (Mobile eXperience) division, he heavily integrated AI features (Galaxy AI) into the S-series flagship phones to combat Apple's dominance in the premium tier.
Source
Timeline: Bristol-Myers Squibb and Samsung side by side
1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1938Samsung
Samsung Group begins
Lee Byung-chul founded Samsung as a trading company before later generations expanded the group into electronics and industry.
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1969Samsung
Samsung Electronics established
Samsung Electronics Industry Co. Ltd. was established as the group entered electronics manufacturing.
1977Samsung
Korea Semiconductor acquired
Samsung acquired Korea Semiconductor, a key step toward memory and component manufacturing leadership.
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
1993Samsung
New Management initiative
Lee Kun-hee launched the New Management push to raise quality, design, and global competitiveness.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2017Samsung
Harman acquisition closes
Samsung completed the Harman acquisition, expanding into connected car systems and premium audio.
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2022Samsung
Jong-Hee Han becomes CEO
Jong-Hee Han became CEO of Samsung Electronics Co. in 2022. A longtime TV business leader who helped keep Samsung the top global TV brand.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2024Samsung
Jun Young-hyun becomes CEO
Jun Young-hyun became CEO of Samsung Electronics Co. in 2024. Head of the semiconductor (Device Solutions) division and memory business; sole CEO for part of 2025 after Han Jong-hee's death, then co-CEO with TM Roh from November 2025.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2025Samsung
TM Roh joins Young Hyun Jun as co-CEO
Samsung named TM Roh Head of Device eXperience and CEO, joining Young Hyun Jun as co-CEO.
2025Samsung
Annual revenue reaches ~$237B (KRW 333.6T)
Samsung Electronics reported ~$237 billion (KRW 333.6 trillion) in 2025 annual revenue and ~$31 billion (KRW 43.6 trillion) in operating profit.
2025Samsung
Roh Tae-moon (TM Roh) becomes CEO
Roh Tae-moon (TM Roh) became CEO of Samsung Electronics Co. in 2025. Longtime head of the mobile business.
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
Acquisitions
Bristol-Myers Squibb
- Orbital Therapeutics2025$1.5B
- Mirati Therapeutics2024$4.8B
- RayzeBio2024$4.1B
- Karuna Therapeutics2024$14B
- Turning Point Therapeutics2022$4.1B
- MyoKardia2020$13.1B
Samsung
- FlaktGroup2025$1.7B
- Xealth2025Undisclosed
- Harman International2017$8B
- SmartThings2014$200M
Questions about Bristol-Myers Squibb vs Samsung
Who is the CEO of Bristol-Myers Squibb Company and Samsung Electronics Co., Ltd.?
Bristol-Myers Squibb Company is led by Christopher Boerner and Samsung Electronics Co., Ltd. is led by Jun Young-hyun and Roh Tae-moon. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bristol-Myers Squibb Company founded vs Samsung Electronics Co., Ltd.?
Bristol-Myers Squibb Company was founded in 1887 — 82 years before Samsung Electronics Co., Ltd., which was founded in 1969. Bristol-Myers Squibb Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Samsung Electronics Co., Ltd..
How many employees does Bristol-Myers Squibb Company have compared to Samsung Electronics Co., Ltd.?
Bristol-Myers Squibb Company employs approximately 32,500 people, while Samsung Electronics Co., Ltd. employs approximately 259,149. Samsung Electronics Co., Ltd. has the larger workforce at 259,149 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bristol-Myers Squibb Company and Samsung Electronics Co., Ltd. headquartered?
Bristol-Myers Squibb Company is headquartered in United States and Samsung Electronics Co., Ltd. is headquartered in South Korea. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Bristol-Myers Squibb Company and Samsung Electronics Co., Ltd.?
Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers. Samsung Electronics Co., Ltd. was founded by Lee Byung-chul.
Which company has a longer operating history — Bristol-Myers Squibb Company or Samsung Electronics Co., Ltd.?
Bristol-Myers Squibb Company has been operating for approximately 139 years, making it the more established of the two companies. Samsung Electronics Co., Ltd. has been in operation for around 57 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs Samsung overview